Stock Evaluator: Haemonetics Corporation (HAE)

Haemonetics Corporation HAE

$108.80 0.58 0.54%
August 21, 2026 4:00:03 PM EST November 10, 2021 Volume: 582,104
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NYSE | DELAYED PRICE
SECTOR INDUSTRY
Health Care Health Care Equipment & Supplies

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient’s overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors. The company was founded in 1971 and is headquartered in Boston, Massachusetts.

Commentary & Analysis


Financial Summary

Share Statistics HAE Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $4,923.7 $407.7 67%
Shares Out (Mil) 45.7 41.3 45%
Institutional Ownership 98.7% 81.4% 81%
Float (Mil) 44.9 34.9 45%
Beta 0.52 0.88 30%
Avg Daily Volume (000s) 927 412 69%
Price Change
(52-week)
99.3% 64.8% 90%
Growth HAE Industry
Median
Percentile
(All Stocks)
Sales (5yr) 8.9% 11.8% 54%
Net Income (5yr) 4.1% (6.0%) 46%
EPS (5yr) 5.8% 10.4% 40
Dividends (5yr) 0.0% 0.0% 0%
Cash Flow (5yr) (26.2%) (16.2%) 24%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 11 11 11
Current EPS $1.290 $5.297 $5.740
Month Ago EPS $1.274 $5.217 $5.626
# Rev Up 1 1 0
# Rev Down 0 0 1
Three Months Ago EPS $1.276 $5.221 $5.767
Year/Year Chg 79.2% 158.4% 210.4%
Financials HAE Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $1,352 $119 55%
Net Income (TTM) (Mil) $96 ($9) 60%
EPS (TTM) $2.071 ($0.400) 72%
Operating Cash Flow (TTM) (Mil) $328 ($3) 65%
Net Cash Flow (TTM) (Mil) ($70) $1 17%
Long-Term Debt (Q1) (Mil) $1,169 $21 68%
Enterprise Value (Q1) (Mil) $5,711 $427 65%
Valuation HAE Industry
Median
Percentile
(All Stocks)
P/B 5.88 3.06 81%
P/E 52.6 27.8 85%
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) 9.1 1.7 93%
Ratios HAE Industry
Median
Percentile
(All Stocks)
Gross Margin 59.3% 58.9% 72%
Net Margin 7.1% (6.9%) 55%
ROA 4.0% (12.7%) 67%
ROE 11.2% (13.1%) 61%
Liabilities to Assets 64.6% 46.0% 59%
F-Score 7 4 82%

Haemonetics Corporation did not pass any screens on 8/20/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors